Product image of Inspra (Eplerenone) supplied by GNH India

Inspra

Active Ingredient:
Eplerenone
Origin:
EU

Inspra (Eplerenone)

Eplerenone, the active ingredient in Inspra, is a mineralocorticoid receptor antagonist presented as an oral tablet for oral use. It is prescribed to lower blood pressure in hypertension and to improve outcomes in adults with heart failure by selectively blocking aldosterone receptors, reducing sodium retention and potassium loss, and supporting cardiovascular health.

GNH India supplies Inspra as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global markets.

Manufacturer / TM Owner

Upjohn Eesv

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

  • Eplerenone is used in conditions where excess aldosterone contributes to cardiovascular disease.
  • Hypertension: lowers systolic and diastolic blood pressure in adult patients.
  • Heart failure: reduces risk of hospitalization and cardiovascular death in patients with reduced ejection fraction.
  • Post‑myocardial infarction with left‑ventricular dysfunction: helps prevent progression of heart failure after an acute coronary event.

How It Works

  • Eplerenone selectively binds to the mineralocorticoid (aldosterone) receptor in the distal nephron, blocking aldosterone‑mediated transcription. This inhibition decreases sodium reabsorption and water retention while reducing potassium excretion, leading to lowered plasma volume and blood pressure, and attenuating cardiac remodeling in heart‑failure patients.

Side Effects

Eplerenone may cause a range of adverse reactions, which are grouped by frequency.

Common Side Effects

  • Hyperkalemia: elevated serum potassium levels.
  • Dizziness: sensation of light‑headedness, especially on standing.
  • Headache: mild to moderate intensity.
  • Fatigue: generalized tiredness.

Serious or Rare Side Effects

  • Severe hyperkalemia leading to cardiac arrhythmia.
  • Acute renal failure or worsening of existing renal impairment.
  • Angioedema: rapid swelling of face, lips, or airway.
  • Hepatic injury: elevated liver enzymes or hepatitis.

Precautions & Warnings

  • When prescribing eplerenone, clinicians should consider several safety measures.
  • Monitor serum potassium: check levels before initiation and periodically during therapy.
  • Assess renal function: evaluate creatinine clearance prior to and during treatment.
  • Use caution in diabetes: patients have an increased risk of hyperkalemia.
  • Avoid in severe hepatic impairment: drug metabolism may be compromised.
  • Contraindicated in hyperkalemia: do not use if serum potassium exceeds 5.0 mEq/L.
  • Store at room temperature: keep in the original packaging, protect from moisture and light.

Avoid Interactions

Eplerenone can interact with other medicines, altering potassium balance or renal function.

Major Interactions (Avoid)

  • ACE inhibitors and ARBs: combined use may cause dangerous hyperkalemia.
  • Potassium‑sparing diuretics (e.g., spironolactone, amiloride): additive effect on potassium.
  • Potassium supplements: increase risk of hyperkalemia.
  • Trimethoprim‑sulfamethoxazole: may raise potassium levels.

Moderate Interactions (Monitor Closely)

  • NSAIDs: may reduce renal clearance and raise potassium.
  • Digoxin: increased risk of toxicity in renal impairment.
  • Lithium: altered lithium clearance; monitor serum levels.

Frequently Asked Questions

Inspra, whose active ingredient is eplerenone, is prescribed to treat hypertension and to improve outcomes in adults with heart failure. It works by blocking aldosterone receptors, helping to lower blood pressure and reduce the risk of heart‑failure‑related hospitalizations.

Eplerenone selectively antagonizes the mineralocorticoid (aldosterone) receptor in the kidney. By blocking aldosterone‑driven sodium reabsorption, it promotes sodium excretion, reduces water retention, and conserves potassium, which together lower blood pressure and lessen cardiac remodeling in heart‑failure patients.

The dose of Inspra is individualized by the prescribing clinician based on the patient’s condition, renal function, and potassium levels. The prescriber determines the appropriate starting dose and any subsequent adjustments.

The safety of eplerenone in pregnancy and lactation has not been established. It is generally avoided unless the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified health professional.

To request Inspra, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Inspra (eplerenone) is more selective for the aldosterone receptor than some older agents, resulting in a lower incidence of hormonal side effects such as gynecomastia. Its efficacy in lowering blood pressure and improving heart‑failure outcomes is comparable, while its safety profile may be more favorable for certain patients.

Inspra tablets should be stored at room temperature, below 25 °C, in the original container. Keep them away from moisture, direct sunlight, and excessive heat to maintain product stability.

Inspra is taken orally, usually once daily, with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed unless specifically instructed.

The most serious risks include severe hyperkalemia, which can cause cardiac arrhythmias, and acute renal impairment. Patients should have regular monitoring of serum potassium and kidney function, and the drug should be stopped if dangerous elevations occur.

Inspra is contraindicated in patients with known hypersensitivity to eplerenone, those with serum potassium levels above 5.0 mEq/L, and individuals with severe renal or hepatic impairment. It should also be avoided in patients taking other potassium‑sparing agents without close monitoring.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Eplerenone

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT